RenovoRx (NASDAQ:RNXT) is a clinical‐stage biopharmaceutical company focused on the development of targeted regional therapies for patients with solid tumors. The company’s proprietary technology platform, known as the RenovoPortal™ System, enables isolated, pressurized delivery of therapeutic agents directly to tumors in the liver, pancreas and other organs. By maximizing local drug concentration while limiting systemic exposure, RenovoRx aims to enhance antitumor activity and reduce off‐target toxicities compared with conventional intravenous chemotherapy.
The RenovoPortal System consists of a minimally invasive catheter and pump designed to temporarily occlude blood flow and infuse drugs under controlled pressure. RenovoRx has conducted multiple Phase I/II clinical trials evaluating the safety and efficacy of its platform combined with standard-of-care chemotherapeutics, including irinotecan‐based regimens, in patients with metastatic colorectal and pancreatic cancers. Preliminary data have demonstrated encouraging response rates and a manageable safety profile, supporting further development in larger studies.
Founded in 2015 and headquartered in Los Angeles, RenovoRx completed a business combination transaction in early 2021 and is traded on the NASDAQ under the symbol RNXT. The company’s leadership team is led by President and Chief Executive Officer William A. Burns, whose prior experience spans oncology drug development and interventional radiology. Supporting the executive team are professionals with backgrounds in clinical operations, regulatory affairs and medical affairs, working to advance ongoing trials in the United States and select international sites.
Looking ahead, RenovoRx plans to expand its clinical program into additional indications and explore potential combinations with immunotherapy and targeted agents. The company is also seeking strategic partnerships and investigations to extend its localized drug delivery approach to a broader range of solid tumors, positioning its platform as a versatile tool in precision oncology.
